Table 4.
Costs saved by switching from TIV to QIV for the targeted population in Uruguay during an average influenza season and ICERs (base case).
| Age group (years) | Physician consultations |
Hospitalizations | Prescribed drugs | OTC drugs | Productivity losses due to illness | Productivity losses due to death | ICER (cost per QALY)* |
|
|---|---|---|---|---|---|---|---|---|
| Payor perspective | Societal perspective | |||||||
| ≤4 | $17,044 | $2,144 | $278 | $129 | NA | NA | $23,461 | $23,434 |
| 5–19 high-risk | $5,809 | $62 | $190 | $110 | $124 | $0 | $24,320 | $24,181 |
| 20–49 high-risk | $3,054 | $125 | $100 | $60 | $2,587 | $10 | $97,256 | $94,909 |
| 50–64 high-risk | $1,860 | $350 | $61 | $36 | $1,302 | $77 | $56,368 | $55,238 |
| ≥65 | $13,702 | $4,879 | $448 | $174 | $493 | $220 | $12,291 | $12,259 |
| Total | $41,470 | $7,560 | $1,076 | $509 | $4,505 | $307 | $18,368 | $18,224 |
ICER, incremental cost-effectiveness ratio; NA, not applicable; OTC, over-the-counter; QALY, quality-adjusted life-year.
*All costs are shown as USD.